Management of Portal Hypertension in Patients with Hepatocellular Carcinoma on Systemic Treatment: Current Evidence and Future Perspectives
Cancers · 31.03.2024 · 16 (7) · 1388
DOI: 10.3390/cancers16071388 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 31.03.2024. Verfasst von Valeria De Gaetano und 6 weiteren Autor:innen. Beteiligte Einrichtung: Liver Unit, Centro Malattie dell'Apparato Digerente (CEMAD), Medicina Interna e Gastroenterologia, Fondazione Policlinico Universitario GemelliIstitu…. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 107 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The management of CSPH in patients undergoing systemic treatment for HCC has emerged as a critical concern due to the absence of reliable diagnostic criteria and uncertainties surrounding therapeutic approaches. This review aims to underscore the primary pathophysiological aspects linking HCC and PH, while also addressing the current and emerging clinical strategies for the management of portal hypertension. A review of studies from January 2003 to June 2023 was conducted using the PubMed database and employing MeSH terms, such as “hepatocellular carcinoma”, “immune checkpoint inhibitors”, “systemic therapy”, “portal hypertension”, “variceal bleeding” and “tyrosine kinase inhibitors”. Despite promising results of tyrosine kinase inhibitors in animal models for PH and fibrosis, only Sorafenib has demonstrated similar effects in human studies, whereas Lenvatinib appears to promote PH development. The impact of Atezolizumab/Bevacizumab on PH remains uncertain, with an increasing risk of bleeding related to Bevacizumab in patients with prior variceal hemorrhage. Given the absence of specific guidelines, endoscopic surveillance during treatment is advisable, and primary and secondary prophylaxis of variceal bleeding should adhere to the Baveno VII recommendations. Furthermore, in patients with advanced HCC, refinement of diagnostic criteria for CSPH and guidelines for its surveillance are warranted.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Liver Unit, Centro Malattie dell'Apparato Digerente (CEMAD), Medicina Interna e Gastroenterologia, Fondazione Policlinico Universitario GemelliIstituto di Ricovero e Cura a Carattere Scientifico, IRCCS, 00168 Rome, Ital…
- Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
ORCID-Profile: Lucia Cerrito, Francesco Santopaolo, Leonardo Stella, Antonio Gasbarrini
Zitieren
APA
De Gaetano, V., Pallozzi, M., Cerrito, L., Santopaolo, F., Stella, L., Gasbarrini, A., & Ponziani, F. R. (2024). Management of Portal Hypertension in Patients with Hepatocellular Carcinoma on Systemic Treatment: Current Evidence and Future Perspectives. Cancers, 16(7), 1388. https://doi.org/10.3390/cancers16071388
Vancouver
De Gaetano V, Pallozzi M, Cerrito L, Santopaolo F, Stella L, Gasbarrini A, et al. Management of Portal Hypertension in Patients with Hepatocellular Carcinoma on Systemic Treatment: Current Evidence and Future Perspectives. Cancers. 2024;16(7):1388. doi:10.3390/cancers16071388
BibTeX
@article{DeGaetano2024,
author = {De Gaetano, Valeria and Pallozzi, Maria and Cerrito, Lucia and Santopaolo, Francesco and Stella, Leonardo and Gasbarrini, Antonio and Ponziani, Francesca Romana},
title = {Management of Portal Hypertension in Patients with Hepatocellular Carcinoma on Systemic Treatment: Current Evidence and Future Perspectives},
journal = {Cancers},
year = {2024},
volume = {16},
number = {7},
pages = {1388},
doi = {10.3390/cancers16071388}
}
EUVIMED